← Back to Screener
OraSure Technologies Inc (OSUR)
Price$3.19
Favorite Metrics
Price vs S&P 500 (26W)-1.63%
Price vs S&P 500 (4W)-2.37%
Market Capitalization$221.20M
All Metrics
P/CF (Annual)7.82x
Book Value / Share (Quarterly)$4.84
P/TBV (Annual)0.54x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-33.29%
Cash Flow / Share (Quarterly)$-0.76
Price vs S&P 500 (YTD)26.44%
Gross Margin (TTM)42.22%
Net Profit Margin (TTM)-59.76%
EPS (TTM)$-0.94
10-Day Avg Trading Volume0.30M
EPS Excl Extra (TTM)$-0.94
Revenue Growth (5Y)-7.70%
EPS (Annual)$-0.94
ROI (Annual)-20.16%
Gross Margin (Annual)42.22%
Net Profit Margin (5Y Avg)-14.30%
Cash / Share (Quarterly)$2.83
Revenue Growth QoQ (YoY)-28.53%
ROA (Last FY)-17.05%
Revenue Growth TTM (YoY)-38.10%
EBITD / Share (TTM)$-0.77
ROE (5Y Avg)-4.68%
Operating Margin (TTM)-62.57%
Cash Flow / Share (Annual)$-0.76
P/B Ratio0.65x
P/B Ratio (Quarterly)0.51x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)0.19x
Net Interest Coverage (TTM)-70.76x
ROA (TTM)-15.90%
EV / EBITDA (TTM)0.87x
EPS Incl Extra (Annual)$-0.94
Current Ratio (Annual)6.58x
Quick Ratio (Quarterly)5.67x
3-Month Avg Trading Volume0.54M
52-Week Price Return8.22%
EV / Free Cash Flow (Annual)-0.10x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.57
P/S Ratio (Annual)1.92x
Asset Turnover (Annual)0.29x
52-Week High$3.82
Operating Margin (5Y Avg)-16.00%
EPS Excl Extra (Annual)$-0.94
CapEx CAGR (5Y)-32.03%
Tangible BV CAGR (5Y)-3.31%
26-Week Price Return7.12%
Quick Ratio (Annual)5.67x
13-Week Price Return17.25%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.58x
Enterprise Value$22.089
Revenue / Share Growth (5Y)-9.26%
Asset Turnover (TTM)0.27x
Book Value / Share Growth (5Y)-2.73%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.04x
Pretax Margin (Annual)-56.15%
Cash / Share (Annual)$2.83
3-Month Return Std Dev48.71%
Gross Margin (5Y Avg)43.21%
Net Income / Employee (TTM)$-0
ROE (Last FY)-20.17%
Net Interest Coverage (Annual)-33.20x
EPS Basic Excl Extra (Annual)$-0.94
P/FCF (TTM)3.46x
Receivables Turnover (TTM)5.00x
EV / Free Cash Flow (TTM)4.96x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.94
Receivables Turnover (Annual)5.00x
ROI (TTM)-18.57%
P/S Ratio (TTM)1.92x
Pretax Margin (5Y Avg)-11.83%
Revenue / Share (Annual)$1.57
Tangible BV / Share (Annual)$4.57
Free OCF CAGR (5Y)117.00%
Price vs S&P 500 (52W)-26.88%
Year-to-Date Return30.58%
5-Day Price Return2.60%
EPS Normalized (Annual)$-0.94
ROA (5Y Avg)-3.81%
Net Profit Margin (Annual)-59.76%
Month-to-Date Return5.33%
Cash Flow / Share (TTM)$0.96
EBITD / Share (Annual)$-0.79
Operating Margin (Annual)-62.57%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-4.67%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.94
P/TBV (Quarterly)0.54x
P/B Ratio (Annual)0.51x
Inventory Turnover (TTM)2.04x
Pretax Margin (TTM)-56.15%
Book Value / Share (Annual)$4.84
Price vs S&P 500 (13W)14.39%
Beta0.95x
P/FCF (Annual)9.38x
Revenue / Share (TTM)$1.61
ROE (TTM)-18.58%
52-Week Low$2.08
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
OSUROraSure Technologies Inc | 1.92x | -7.70% | 42.22% | -62.57% | $3.19 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
OraSure Technologies manufactures oral fluid diagnostic devices and specimen collection kits for infectious disease testing. The diagnostics segment provides rapid tests for HIV and HCV, while the larger molecular solutions segment offers collection and transport kits for genetic material and infectious disease screening, including COVID-19 testing. The company generates the majority of its revenue from molecular solutions, primarily serving U.S. customers.